Summary The efficacy and safety of gemcitabine at a starting dose of 800 mg m2 administered once a week for 3 weeks with 1 week's rest was investigated in chemonaive patients with advanced and/or metastatic pancreatic cancer. Of 34 patients, 32 were evaluable for efficacy, 20 patients had metastatic stage IV disease, 25 had a performance status of I and 26 (76%) patients has significant pain on presentation. All responses were independently validated by an external oncology review board: two patients achieved a partial response that lasted 5.8 and 5.2 months (6.3%) and six patients were stable for at least 4 weeks. The median duration of survival for evaluable patients was 6.3 months (range 1.6-19.2 months). The tumour markers, CEA, CA 19-9 and CA 195 were serially measured in 16 patients. There was a good correlation with tumour response when all three markers were significantly decreased. In 4 of 16 patients, tumour marker levels decreased by > 60%, including the two responders, one patient who survived for 12 months and one patient who showed objective tumour shrinkage but was deemed ineligible for response evaluation because the disease was considered not to be bidimensionally measurable. Symptomatic benefits included improvement in performance status (17.2%), analgesic requirement (7.4%), pain score (28.6%) and nausea (27.3%). The mean number of cycles administered was 2.5 and the mean dosage received was 890 mg m2 per injection. Seventy-four per cent of dose administrations were given on schedule. Toxicity, particularly haematological toxicity, reported as the maximum WHO grade experienced by patients was mild. Infective episodes were rare and limited to WHO grade 2 (6.7%). Nausea and vomitimg was generally modest (WHO grade 3, 26.7%). Other side-effects included mild transient flu-like symptoms (seven patients) and peripheral oedema (three patients), which was not associated with abnormal cardiac hepatic or renal function. Gemcitabine has modest activity in pancreatic cancer, a limited positive improvement on a range of patient benefit parameters and has a mild toxicity profile. For these reasons and because of its novel mode of action, gemcitabine warrants further investigation in combination studies in pancreatic cancer.
Patients with pancreatic cancer have an extremely poor prognosis, most patients presenting with obvious metastases or unresectable locally advanced disease. In the European Union, 60% of patients with pancreatic cancer are aged > 65 years (Jensen et al., 1990) . Patients are often debilitated as a result of the tumour and concomitant illnesses. Chemotherapeutic regimens commonly include 5-FU (5 fluorouracil). As a single agent, 5-FU quoted response rates are 7 -30% (Brennan et al., 1993) , with little additional response in combination therapy and complete responses being extremely rare and with no impact on survival. In phase II trials, the median survival of patients with metastatic pancreatic cancer is reported to be 12 -14 weeks (Brennan et al., 1993) . Many other agents have been used in this disease but as yet there is no standard chemotherapy regimen, leaving an urgent need for the identification of new active agents. It is difficult to assess treatment activity against pancreatic cancer using standard radiological techniques, and it is worthwhile using other criteria to assess objective response (tumour markers) and symptomatic status (performance and pain scores).
Gemcitabine (2, dFdC ) is a novel nucleoside analogue, with activity reported in a variety of solid tumours. Within the cell, the parent prodrug is converted into phosphorylated metabolites, which are cytotoxic: (1) gemcitabine disphosphate (dFdCDP) inhibits ribonucleotide reductase, the principal enzyme in the formation of deoxynucleotide triphosphates for normal DNA synthesis; (2) gemcitabine triphosphate (dFdCTP) competes with endogenous deoxycytidine triphosphate for incorporation into DNA. Once gemcitabine triphosphate is incorporated into DNA, one more nucleotide is allowed to pair before the DNA replication is terminated. By this process, termed 'masked-chain termination', the DNA chain is less easily repaired by proofreading exonuclease enzymes (Huang et al., 1991) . Also of importance is that there are at least three mechanisms by which gemcitabine 'self-potentiates' its activity: (1) gemcitabine disphosphate indirectly reduces the inhibition of the rate-limiting enzyme (deoxycytidine kinase), which converts gemcitabine into the active triphosphate (Plunkett et al., 1989) ; (2) gemcitabine disphosphate also indirectly inhibits the principal enzyme (dCMP deaminase) involved in the cellular clearance of gemcitabine (Xu et al., 1992) ; (3) gemcitabine triphosphate directly inhibits activation of dCMP deaminase (Heinemann et al., 1988) . This may explain why, compared with ara-C, gemcitabine within tumour cells is seen at higher levels and for longer periods (Hertel et al., 1990) , and has much greater and broader activity in a panel of murine and human solid tumour models (Hertel et al., 1990) .
Gemcitabine has proven efficacy in phase II trials of a number of solid tumours. These tumours include non-smallcell lung cancer (Shepherd et al., 1993; Abratt et al., 1994; Anderson et al., 1994) , advanced previously treated epithelial ovarian cancer , advanced breast cancer (Carmichael et al., 1993) , and small-cell lung cancer (Cormier et al., 1994) . In a phase II study conducted with a similar regimen, gemcitabine produced a.response rate of 11% in patients with advanced pancreatic cancer (Casper et al., 1994) .
This single-agent phase II study was designed (1) to determine the objective response rate to single-agent gemcitabine given weekly for 3 weeks followed by 1 week of rest (one cycle) to chemonaive patients with locally advanced and/or metastatic pancreatic cancer; (2) transaminase (AST, SGOT) and alanine transaminase (ALT, SGPT) < 3 x normal, prothrombin and partial thromboplastin time < 1.5 x normal.
A starting dose of 800 mg m-2 was chosen based on phase I data (Abbruzzese et al., 1991) . However, these phase I patients had been heavily pretreated, and it became apparent that a higher dose of gemcitabine could be tolerated in chemonaive patients. Therefore, the starting dose was increased to 1000 mg m-2 from the sixth patient onwards.
Patients completing one cycle of therapy could have their subsequent dose increased by up to 20%, provided there had been no significant changes in haematological or nonhaematological parameters. Dose modification was based on blood cell counts before injections. The dose was reduced by 50% for grade 2 haematological toxicity and omitted for grade 3 toxicity or greater.
Efficacy was assessed by the following: full medical history and physical examination; evaluation of WHO Zubrod performance status (physician assessed); tumour measurement by appropriate radiological tests; chest radiograph; and evaluation of analgesic consumption for pain using the following six point scale: 0, none; 1, aspirin, paracetamol, nonsteroidal anti-inflammatory drugs (NSAID); 2, codeine, dextropropoxyphene, pentazocine, buprenorphine; 3, morphine sulphate, methadone, pethidine; 4, parenteral opiates; 5, neurosurgical procedures. When combinations of analgesics were used, the highest score was adopted.
In 16 patients serial measurements of serum CEA, CA 19-9 and CA 19-5 were recorded on the first day of each cycle before gemcitabine therapy.
Each investigator-determined response was evaluated by an external oncology review board (ORB), which reviewed the clinical history, signs, symptoms and appropriate radiological tests. Evaluations were conducted using established WHO criteria for response (World Health Organization, 1979 
Results

Patient disposition
Only two patients failed to qualify according to the protocol, one owing to lack of bi-dimensional lesions on entry into the study and one owing to insufficient therapy (this patient was enrolled onto the study but did not receive any gemcitabine). 59 .4%) and analgesics were also taken frequently.
Of 34 patients enrolled, 20 patients discontinued therapy because of lack of efficacy. In addition, two patients on treatment suffered an early death as a result of disease progression and three patients discontinued treatment because of adverse events, two possibly drug related (one patient with leucopenia (no sepsis) and one patient with thrombocytopenia, but no clinically significant bleeding).
Summary of dose administrations A total of 74% of dose administrations were given on schedule, 4% were omitted and 14% reduced. The most common reason for dose reduction was leucopenia (65%) followed by thrombocytopenia (24%). Neither of these events showed a cumulative tendency. This suggests that gemcitabine was well tolerated (Figure 1) injection basis, but represent the worst grades experienced by patients during the whole study period (Figures 2-4) . Haematological toxicity was mild ( Figure 2 ). WHO grade 3 and 4 leucopenia was 6.1 and 0% and one patient was discontinued owing to a grade 3 leucocyte toxicity in the absence of infection. The incidence of infection associated with this level of leucopenia was low (6.7% patients at grade 2). WHO grade 3 and 4 neutropenia was 18.2 and 6.3%. There was no WHO grade 4 anaemia, with grade 3 toxicity in one patient and only four patients requiring blood transfusions. WHO grade 3 and 4 platelet toxicity was 6.1 and 3.0%, which resulted in discontinuation for one patient and a platelet transfusion for one patient who was asymptomatic. Liver and renal toxicity were rare and when present were mild and transient (Figures 3 and 4) . There was no evidence of non-reversible cumulative organ toxicity.
No WHO grade 4 toxicities were reported for any of the 16 symptomatic parameters assessed (Table III) . WHO grade 3 toxicity was reported only for nausea and vomiting (26.7%), diarrhoea (3.3%) and pain (3.3%).
Other symptomatic toxicities, not WHO graded, were classified as mild, moderate or severe. Nine patients experienced lethargy, some presumed to be drug-related and some as a result of underlying disease, but it is difficult to separate these causes. Flu-like symptoms were experienced in seven patients and peripheral oedema in three patients, which was not associated with abnormal cardiac, hepatic or renal function.
Discussion
The initial gemcitabine dosing schedule of 800 mg m-2 was increased to 1000 mg m-2 after the fourth patient enrolled, as a result of the low toxicity experienced in this study and also in other phase II studies with previously untreated patients. Two patients (6.3%) had partial responses of at least 4 weeks duration. These responses were confirmed by an external ORB. In both responders all three tumour markers (CEA, CA19-9, CA195) were significantly decreased. There were two other patients in whom all three markers significantly decreased, one patient with a duration of survival of 12 months, which is unusual in a patient with advanced pancreatic cancer, and one patient with objective tumour shrinkage but whose disease was judged not to be bidimensionally measurable and was deemed ineligible for response evaluation. These data show a good correlation with objective tumour response when all three markers are considered. It would be interesting to conduct further studies looking at this relationship between these three markers and tumour response.
A proportion of patients benefited from improvements in a number of secondary efficacy and disease-related symptom parameters, such as performance status (17.2%), analgesic requirement (7.4%), pain score (28.6%) and nausea (27.3%). The median durations of improvement were 7, 10.9, 9.3 and 12 weeks respectively.
Gemcitabine was well tolerated and WHO grade 3 and 4 toxicity was infrequent. Haematological toxicity was particularly modest. There was no WHO grade 3 or 4 infection, which reflected the low level and duration of myelosuppression. Transient elevations of hepatic enzymes were commonly reported but were mild and of no apparent clinical relevance. There was no WHO grade 3 or 4 alopecia. Pancreatic cancer patients would be expected occasionally to experience nausea and vomiting and WHO grade 3 nausea and vomiting was experienced in only 26.7% of patients with no grade 4 toxicity.
In an earlier study with gemcitabine in the same schedule but with a starting dose of 800 mg m-2, a response rate of 11% has been reported (Casper et al., 1994) . In both pancreatic cancer studies, the response rates with gemcitabine have been independently validated by an external ORB, and still compare well with response rates reported in other studies that were not independently validated. No single (Brennan et al., 1993) .
Pancreatic cancer presents special difficulties, both in the objective measurement of tumour size and in assessing the degree of patient benefit afforded by any tumour shrinkage. In patients with pancreatic cancer it is often difficult to obtain accurate tumour measurements because of the location of the pancreas in the retroperitoneum and the difficulty in distinguishing tumour from normal pancreas on CT. Determination of objective response is therefore difficult and unreliable in most patients. This may explain the widely varying response rates reported in pancreatic cancer for the same agents. Whereas for most cancers tumour-related symptoms are closely related to tumour bulk, as a result of the location of the tumour in pancreatic cancer even small reductions in tumour size may result in significant clinical benefit in some patients. In the treatment of metastatic pancreatic cancer therapeutic options are limited and improvement in quality of life therefore assumes a high priority. The beneficial effects of gemcitabine on these secondary measures were somewhat less than in the study by Casper et al. (1994) but are nevertheless promising. The suggestion of improverovements in pain score, analgesia requirement and performance status are encouraging. Furthermore, gemcitabine has shown remarkably little haematological, liver, renal or symptomatic toxicity.
In conclusion, in this study the independently validated response rate to gemcitabine in patients with advanced/ metastatic pancreatic cancer was 6.3%. This compares with the 11% reported by Casper et al. (1994) and is equivalent to the activity of 5-FU as a single agent or in combination. Although this level of objective tumour response can at best be described as modest, symptomatic benefit was reported for patients on the study. Recently a prospective randomised trial was performed in pancreatic cancer patients to evaluate symptom improvement (pain) and Karnofsky performance status according to strict criteria (Moore et al., 1995) . In this trial of 126 patients randomised to gemcitabine 1000 mg m-2 vs weekly 5-FU 600 mg m-2, significantly more patients (P = 0.0022) derived clinical benefit in the gemcitabine (23.8%) vs the 5-FU group (4.8%). Median survival was also significantly (P = 0.0025) higher, with 24% of gemcitabine patients treated with gemcitabine and 6% of 5-FU patients alive at 9 months. These data are also supported by a single-arm 63 patient study, which showed that 27% of 5-FU refractory patients treated with gemcitabine derived clinical benefit (Rothenberg et al., 1995) . These data on tumour response, symptom benefit and survival, taken together with its modest toxicity and novel mechanism of action, suggest that gemcitabine warrants further clinical investigation both as a single agent evaluating other schedules and in combination with other agents such as modulated 5-FU.
